PTCT earnings date and last-quarter result: next report 2026-07-30, last quarter beat, P/E -33.59. Updated 2026-07-23.
PTC Therapeutics (PTCT) Research Hub
PTC Therapeutics (PTCT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 61.07 USD (+0.79%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -33.59, market cap 6.46B. This hub links to the full technical, earnings and options research available for PTCT.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 61.07 USD (+0.79%) |
| 52-week range | 58.8 USD – 90.87 USD |
| Trend regime | Range |
| 14-day RSI | 43 (Bearish) |
| Trailing P/E | -33.59 |
| Market cap | 6.46B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for PTCT
Covered Call on PTCT: how it works, illustrative setup around the real 61.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PTCT: how it works, illustrative setup around the real 61.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PTCT: how it works, illustrative setup around the real 61.07 USD price, max profit/loss, breakeven and when to use it. Educational.
PTCT technical analysis: range, last 61.07 USD, RSI 43, 52w range 58.8 USD–90.87 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is PTCT in?
PTC Therapeutics (PTCT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PTCT in an uptrend or downtrend?
As of 2026-10-26, PTCT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PTCT's trailing P/E ratio?
PTCT's trailing P/E is -33.59, with a market cap of 6.46B. See the earnings research page for full valuation detail.
When does PTCT next report earnings?
PTCT is next scheduled to report earnings on 2026-07-30.